Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts.

Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kwak C, Choudhary GS, Gordon-Mitchell S, Aluri S, Bhattacharyya S, Sahu S, Bhagat P, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Guerrero PA, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D, Maitra A, Verma A.

Elife. 2019 Nov 1;8. pii: e50663. doi: 10.7554/eLife.50663.

2.

Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment.

Mishra D, Banerjee D.

Cancers (Basel). 2019 May 29;11(6). pii: E750. doi: 10.3390/cancers11060750. Review.

3.

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR.

Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7.

4.

Activation and Differentiation of Mesenchymal Stem Cells.

Mishra PJ, Banerjee D.

Methods Mol Biol. 2017;1554:201-209. doi: 10.1007/978-1-4939-6759-9_13.

PMID:
28185193
5.

Tumor stroma interaction is mediated by monocarboxylate metabolism.

Patel BB, Ackerstaff E, Serganova IS, Kerrigan JE, Blasberg RG, Koutcher JA, Banerjee D.

Exp Cell Res. 2017 Mar 1;352(1):20-33. doi: 10.1016/j.yexcr.2017.01.013. Epub 2017 Jan 26.

6.
7.

Subverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic Opportunities.

Rothschild E, Banerjee D.

Breast Cancer (Auckl). 2015 Sep 15;9(Suppl 2):7-15. doi: 10.4137/BCBCR.S29423. eCollection 2015. Review.

8.

Distribution of hepatitis B virus genotype and cancer predicting precore and basal core promoter mutations.

Agarwal AK, Sen S, Banerjee D, Srivastava R, Praharaj AK.

Med J Armed Forces India. 2015 Jul;71(3):225-32. doi: 10.1016/j.mjafi.2015.04.003. Epub 2015 Jun 9.

9.

Practical Issues with the Use of Stem Cells for Cancer Gene Therapy.

Nouri FS, Banerjee D, Hatefi A.

Stem Cell Rev Rep. 2015 Oct;11(5):688-98. doi: 10.1007/s12015-015-9605-9. Review.

10.

Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Katanov C, Lerrer S, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D, Ben-Baruch A.

Stem Cell Res Ther. 2015 May 1;6:87. doi: 10.1186/s13287-015-0080-7.

11.

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Oncotarget. 2014 Feb 28;5(4):901-7.

12.

P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms.

Lin SY, Dolfi SC, Amiri S, Li J, Budak-Alpdogan T, Lee KC, Derenzo C, Banerjee D, Glod J.

Int J Oncol. 2013 Dec;43(6):1817-23. doi: 10.3892/ijo.2013.2109. Epub 2013 Sep 23.

13.

Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE, Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Cancer Biol Ther. 2013 Aug;14(8):742-51. doi: 10.4161/cbt.25184. Epub 2013 Jun 3.

14.

Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.

Hsieh YC, Tedeschi P, Adebisi Lawal R, Banerjee D, Scotto K, Kerrigan JE, Lee KC, Johnson-Farley N, Bertino JR, Abali EE.

Mol Pharmacol. 2013 Feb;83(2):339-53. doi: 10.1124/mol.112.080218. Epub 2012 Nov 29.

15.

Post-prandial paradoxical filling of gall bladder in patients with acute hepatitis: Myth or reality?

Debnath J, George RA, Satija L, Mathur A, Banerjee D, Mishra S.

Med J Armed Forces India. 2012 Oct;68(4):346-9. doi: 10.1016/j.mjafi.2012.04.021. Epub 2012 Jul 20.

16.

Cell-free derivatives from mesenchymal stem cells are effective in wound therapy.

Mishra PJ, Mishra PJ, Banerjee D.

World J Stem Cells. 2012 May 26;4(5):35-43.

17.

A second target of benzamide riboside: dihydrofolate reductase.

Roussel B, Johnson-Farley N, Kerrigan JE, Scotto KW, Banerjee D, Felczak K, Pankiewicz KW, Gounder M, Lin H, Abali EE, Bertino JR.

Cancer Biol Ther. 2012 Nov;13(13):1290-8. doi: 10.4161/cbt.21786. Epub 2012 Sep 6.

18.

Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion.

Anton K, Banerjee D, Glod J.

PLoS One. 2012;7(4):e35036. doi: 10.1371/journal.pone.0035036. Epub 2012 Apr 4.

19.

Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.

Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D.

Cancer Biol Ther. 2012 Jan 15;13(2):114-22. doi: 10.4161/cbt.13.2.18876.

20.

Operative management of closed intra-articular fractures of distal end of humerus in adults.

Bhattacharyya A, Jha AK, Chatterjee D, Ghosh B, Roy SK, Banerjee D.

J Indian Med Assoc. 2011 Jun;109(6):418, 423.

PMID:
22315773

Supplemental Content

Loading ...
Support Center